DNA RESEARCH is a pioneering open-access journal published by Oxford University Press, dedicated to advancing the field of genetics and molecular biology. Since its inception in 1994, the journal has been at the forefront of scientific innovation, providing a global platform for researchers to publish high-quality findings that drive the understanding of DNA and its implications in medicine. With an impactful presence characterized by a Q2 ranking in Genetics, a Q1 ranking in Medicine (miscellaneous), and a Q2 ranking in Molecular Biology as per the latest 2023 assessments, DNA RESEARCH stands as a vital resource for both established scholars and emerging scientists. The journal's diverse range of articles caters to a wide audience, fostering collaboration and the sharing of knowledge. Researchers, professionals, and students alike will find an abundance of cutting-edge research and insights that can inform their work and further their understanding of this critical scientific domain. For more information and to access articles, visit the journal's website at Oxford University Press.

CLINICAL DYSMORPHOLOGY, published by Lippincott Williams & Wilkins, is a pivotal journal in the fields of anatomy, genetics, and pediatric health, with a significant focus on the study of congenital disorders and their phenotypic manifestations. Established in 1992, this esteemed journal has contributed valuable insights into the understanding of dysmorphic syndromes and their clinical implications, making it an essential resource for researchers, clinicians, and students alike. With an impact factor indicative of its robust scholarly influence, CLINICAL DYSMORPHOLOGY engages a diverse readership through specialized articles, case studies, and reviews that advance the knowledge of genetic conditions and associated anatomical anomalies. Although it operates under a non-open access model, the journal is highly regarded with a 2023 ranking of Q3 in Anatomy and Q4 in several other relevant categories, reflecting its ongoing commitment to quality research in the domain of clinical medicine. Researchers and professionals are encouraged to contribute to and explore the rich content of this journal as it continues to shape the discourse in dysmorphology and related fields until its expected convergence in 2024.

Leukemia Research is a prominent academic journal dedicated to advancing the field of hematology and oncology, focusing on the latest research developments related to leukemia and other hematological disorders. Founded in 1977 and published by Pergamon-Elsevier Science Ltd in the United Kingdom, this esteemed journal has established itself as a vital resource for researchers and clinicians alike. With an impressive impact factor and categorized in the top quartiles of Cancer Research and Hematology, it provides a platform for high-quality research articles, reviews, and clinical studies that contribute to a deeper understanding of leukemia's complexities. Although not an Open Access journal, Leukemia Research ensures widespread dissemination of knowledge crucial for developing innovative treatment strategies and improving patient outcomes. Researchers, professionals, and students in the fields of hematology and oncology will find this journal an invaluable asset in staying at the forefront of leukemia research, as it prepares to expand its impact through converged years of publication extending into 2024.

Application of Clinical Genetics is a premier open-access journal published by Dove Medical Press Ltd., dedicated to advancing the field of clinical genetics since its inception in 2008. Based in New Zealand, this journal has established itself as a significant resource for researchers, clinicians, and students alike, contributing to the body of knowledge in both genetic medicine and clinical applications. With an impact factor reflecting its contributions to the field, the journal holds positions in the Q2 and Q3 quartiles of the 2023 Genetics categories, showcasing its relevance and scientific merit. Furthermore, it ranks #43 out of 99 in Clinical Genetics and #153 out of 347 in Biochemistry, Genetics, and Molecular Biology, indicating robust performance amongst its peers. The journal’s broad scope, encompassing various aspects of clinical genetics, ensures that it remains at the forefront of critical discussions, innovative research, and applications essential for the progression of personalized medicine. Researchers and professionals are encouraged to explore its openly accessible content that fosters collaboration and the sharing of knowledge in this dynamic and rapidly evolving field.

CONGENITAL ANOMALIES is a notable journal published by WILEY, dedicated to advancing the understanding of congenital disorders and anomalies through high-quality research and clinical insights. With an ISSN of 0914-3505 and an E-ISSN of 1741-4520, this journal has been a key resource for professionals in the fields of pediatrics, embryology, and developmental biology since its inception in 1973, although coverage discontinued in Scopus after 2019 due to evolving standards in publication. The journal is ranked in the 48th percentile in the domain of pediatrics, as well as in the 26th and 14th percentiles respectively for embryology and developmental biology, placing it among respected publications in its category. Although it does not currently offer open access options, its contributions remain vital for researchers, healthcare professionals, and students seeking up-to-date information on congenital anomalies, their origins, and potential interventions. With a commitment to fostering knowledge in this critical area of health science, CONGENITAL ANOMALIES continues to play an important role in the intersection of scientific research and clinical practice.

Journal of Hematology & Oncology, published by BMC, is a leading open-access journal dedicated to the dynamic fields of hematology and oncology, with a continuous publication record since 2008. Based in the United Kingdom, this prestigious journal provides a platform for groundbreaking research, encompassing topics that span cancer research, hematological disorders, and molecular biology. With a remarkable Q1 ranking in multiple categories including Cancer Research, Hematology, Molecular Biology, and Oncology for 2023, it stands as a significant contributor to the scientific community. The journal's rigorous peer-review process ensures the dissemination of high-quality studies that drive advancements in these critical areas of medicine, boasting an impressive Scopus rank in the top echelons of its fields. As an open-access publication, it promotes widespread accessibility and sharing of knowledge, making it an indispensable resource for researchers, clinicians, and students striving to make advancements in understanding and treating hematological and oncological diseases.

CHROMOSOMA is a prestigious journal dedicated to advancing the field of genetics, published by Springer in Germany. With an ISSN of 0009-5915 and an E-ISSN of 1432-0886, this journal has been a cornerstone in the publishing landscape since its inception in 1939, serving as a critical resource for researchers and professionals interested in the intricacies of chromosomal biology. Although it operates on a subscription basis, the journal's rigorous peer-review process ensures the dissemination of high-quality research findings. With a commendable Q2 ranking in both genetic and clinical genetics categories as of 2023, CHROMOSOMA aims to bridge theoretical concepts with practical applications in medicine and biology. Researchers will appreciate its relevance, as indicated by its Scopus ranks and integration of diverse topics ranging from molecular genetics to clinical implications. By fostering collaboration and knowledge-sharing among scholars, CHROMOSOMA continues to shape the future of genetic research.

The Journal of Hematopathology, published by SPRINGER HEIDELBERG, serves as a vital resource in the fields of hematology, histology, and pathology. Established in 2008, this peer-reviewed journal aims to foster the exchange of knowledge among researchers, clinicians, and students by publishing original articles, reviews, and case studies that contribute to the understanding of hematopathological disorders. While the journal currently ranks in the fourth quartile in various categories including hematology and histology, it positions itself as a platform for emergent research and insights, addressing the evolving landscape of blood-related diseases. Although not an open access journal, it provides crucial access to research findings for professionals looking to stay abreast of developments in pathologic diagnostics and therapeutic strategies. As it continues to grow, the journal remains committed to enhancing the knowledge base and scientific discourse in hematopathology.

CYTOLOGIA is a prominent academic journal published by University of Tokyo Cytologia, specializing in the fields of Animal Science, Plant Science, Cell Biology, and Genetics. With origins dating back to 1929, this journal has been at the forefront of cytological research and continues to contribute to advancements in both basic and applied sciences. As of 2023, it holds a respectable position in various Scopus categories, with a Q3 ranking in Animal Science and Zoology and Plant Science, alongside Q4 rankings in Genetics and Cell Biology, reflecting its dedication to quality research dissemination. While currently not an Open Access journal, CYTOLOGIA provides critical insights and findings that are pivotal for researchers, professionals, and students aiming to further their understanding of cytology and its applications in diverse biological fields. With a historical legacy and ongoing relevance, CYTOLOGIA remains a vital resource for anyone engaged in cutting-edge research or seeking comprehensive knowledge in the biological sciences.

GENES CHROMOSOMES & CANCER, published by Wiley, is a premier journal in the intertwined fields of cancer research and genetics. With an ISSN of 1045-2257 and an e-ISSN of 1098-2264, this journal has been a significant outlet for innovative research since its inception in 1989, continuing through to 2024. Positioned in the Q2 quartile of both Cancer Research and Genetics categories in 2023, it reflects a strong impact in the scientific community, as evidenced by its Scopus rankings—99th in Genetics and 83rd in Cancer Research. Though it does not provide open access options, GENES CHROMOSOMES & CANCER offers valuable insights that foster collaboration and discovery among researchers, professionals, and students dedicated to understanding the genetic underpinnings of cancer. With its reputable standing, this journal is a vital resource for those aspiring to contribute meaningful advancements in cancer genetics and therapeutic interventions.